Research programme: monoclonal antibodies mimicking T cell receptors- Agenus/Pure MHC

Drug Profile

Research programme: monoclonal antibodies mimicking T cell receptors- Agenus/Pure MHC

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PhosImmune; Pure MHC
  • Developer Agenus; Pure MHC
  • Class Cancer vaccines; Heat shock proteins; Monoclonal antibodies; Peptide vaccines; Synthetic vaccines
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Mar 2018 Agenus has issued and pending patents for phosphorylated antigenic targets in USA
  • 13 Dec 2016 Agenus Inc. plans a phase I trial for Cancer in USA (NCT02992977)
  • 27 Jan 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top